MedTrace Logo

Safety Study of NY-ESO-1 Protein Vaccine to Treat Cancer Expressing NY-ESO-1

NCT00106158 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2010-11-05

No results posted yet for this study

Summary

The purpose of this study is to assess the safety of repeated doses of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein (CHP-NY-ESO-1) and describe the NY-ESO-1 specific-humoral and cellular immune response to immunization with CHP-NY-ESO-1 in patients with cancer expressing NY-ESO-1.

Conditions

  • Neoplasms

Interventions

BIOLOGICAL

protein vaccination

Sponsors & Collaborators

  • Ludwig Institute for Cancer Research

    lead OTHER

Principal Investigators

  • Eiichi Nakayama, MD., PhD · Dept. of Immunology, Okayama University Schhol of Medicine and Dentistry

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-06-30
Completion
2006-12-31

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00106158 on ClinicalTrials.gov